During the last decade the field of cancer immunotherapy has witnessed impressive
progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell …

Immunotherapy has become an established pillar of cancer treatment improving the prognosis
of many patients with a broad variety of hematological and solid malignancies. The two …

Allogeneic hematopoietic stem cell transplantation is an established treatment modality for
malignant and nonmalignant hematologic diseases. Acute and chronic graft-versus-host …

… Hellmuth MD a h , Michael von Bergwelt-Baildon MD, PhD a c e h i , Matthias Klein MD b
j , Tobias … Charakteristik von 50 hospitalisierten COVID-19-Patienten mit und ohne ARDS …

Background: Severe acute respiratory syndrome corona virus 2 infection causes severe
pneumonia (coronavirus disease 2019 [COVID-19]), but the mechanisms of subsequent …

Globally suppressed T-cell function has been described in many patients with cancer to be
a major hurdle for the development of clinically efficient cancer immunotherapy. Inhibition of …

Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell–related adverse
event and remains poorly understood. In this multicenter analysis, we studied patterns of …

Adoptive T cell therapy (ACT) refers to the therapeutic use of T cells. T cells genetically
engineered to express chimeric antigen receptors (CAR) constitute the most clinically advanced …

Targeted drug delivery with antibody-drug conjugates such as the HER2-directed ado-trastuzumab
emtansine (T-DM1) has emerged as a powerful strategy for cancer therapy. We show …

Background More than 200 clinical trials have been performed using dendritic cells (DC) as
cellular adjuvants in cancer. Yet the key question whether there is a link between immune …